The pain syndrome of PHN is most commonly treated with oral and topical medications.  Orally administered gabapentinoids include gastroretentive gabapentin (Gralise; Depomed), extended-release gabapentin enacarbil (Horizant; XenoPort), immediate-release gabapentin (Neurontin; Pfizer), and pregabalin (Lyrica; Pfizer). Topical treatments include the lidocaine 5% patch (Lidoderm; Endo) and the capsaicin 8% patch (Qutenza; Acorda Therapeutics).2

“Gabapentinoids and lidocaine patch are first-line approved treatments. Capsaicin is a second-line treatment approved by the FDA,” said Massengill. Furthermore, “Tertiary treatments can include short-acting opioids or nonsteroidal anti-inflammatory drugs (NSAIDs). However, these tertiary treatments should be considered only when other options have been exhausted and should only be used for short periods of time.”


Continue Reading

The primary focus of prevention is vaccination, which includes varicella vaccination in childhood and live zoster vaccine (Zostavax; Merck) among adults aged ≥50.
 

Practical Considerations for Postherpetic Neuralgia Management

“Practical considerations should include prevention of shingles followed by, should one be subjected to shingles, a focus to shorten the course of the illness through reduced viral replication and rapid deployment of various treatment strategies to combat the ensuing pain syndrome,” said Massengill.

Insurance coverage and pharmacy benefit managers commonly hinder drug choice. “All medical providers are trained in the evidenced-based approach to the treatment of this and any other condition. However, the black cloud of insurance denials and road blocks prevent best practice approaches in many cases,” said Massengill. In addition, other factors including drug cost, route of administration, potential adverse effects, method of drug metabolism, possible drug-drug interactions, and drug dosing regimens may impact drug choice.

Conclusion

Overall, postherptic neuralgia is a widely variable condition that ranges from mild to severe and prolonged. Treatment plans need to be individualized and focus on shingles outbreak prevention followed by treatment with medication at the lowest possible doses with maximum benefit and fewest adverse effects.

References:

  1. Centers for Disease Control and Prevention (CDC). Shingles (Herpes Zoster). Available at:http://www.cdc.gov/shingles/about/overview.html. Accessed: June 17, 2014. 
  2. Massengill JS, Kittredge JL. Practical considerations in the pharmacological treatment of postherpetic neuralgia for the primary care provider. Journal of Pain Research. 2014 (7): 125-132.